# Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee

> **NCT03349645** · PHASE3 · TERMINATED · sponsor: **Ampio Pharmaceuticals. Inc.** · enrollment: 94 (actual)

## Conditions studied

- Severe Osteoarthritis of the Knee

## Interventions

- **BIOLOGICAL:** 4 mL injection of AMPION™

## Key facts

- **NCT ID:** NCT03349645
- **Lead sponsor:** Ampio Pharmaceuticals. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-08
- **Primary completion:** 2018-10-04
- **Final completion:** 2018-10-04
- **Target enrollment:** 94 (ACTUAL)
- **Why stopped:** Study terminated by Sponsor due to absence of significant safety findings.
- **Last updated:** 2022-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03349645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03349645, "Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03349645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*